Pfizer Inc. (PFE)

43.92
NYSE : Health Technology
Prev Close 44.98
Day Low/High 43.67 / 44.94
52 Wk Low/High 33.20 / 46.47
Avg Volume 22.03M
Exchange NYSE
Shares Outstanding 5.78B
Market Cap 260.01B
EPS 3.60
P/E Ratio 11.39
Div & Yield 1.36 (3.01%)

Latest News

Pfizer Reaches A Global Agreement With AbbVie

Pfizer Reaches A Global Agreement With AbbVie

Pfizer Inc. (NYSE:PFE) today announced that it has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar.

Pfizer Receives Six Months Pediatric Exclusivity For LYRICA® (pregabalin)

Pfizer Receives Six Months Pediatric Exclusivity For LYRICA® (pregabalin)

Pfizer Inc. (NYSE: PFE) today announced that the U.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Chris Boshoff, senior vice president and head, Immuno-Oncology, Early Development and Translational Oncology, at the Evercore ISI HealthConX Conference on...

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.

Bulls Stampeded by Bears as FAANG Stocks Get Trampled

Bulls Stampeded by Bears as FAANG Stocks Get Trampled

A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Monday Madness: Don't Be Afraid of the Big, Bad Bear

Monday Madness: Don't Be Afraid of the Big, Bad Bear

Here's what you're missing on TheStreet.

The Market Is 'Full Blown Bear,' Says Jim Cramer

The Market Is 'Full Blown Bear,' Says Jim Cramer

Worried about the market? Jim Cramer has some advice for investors.

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Shares of the New York City-based pharmaceutical giant are rising on Monday.

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Jim Cramer Reacts to Pfizer's Drug Hikes

Jim Cramer Reacts to Pfizer's Drug Hikes

Jim Cramer responds to the news that the drug company, Pfizer, has hiked rates.

Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline

Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline

Let's check our indicators.

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer may have poked the bear.

Merck KGaA, Darmstadt, Germany, And Pfizer Provide Update On Avelumab In Platinum-Resistant/Refractory Ovarian Cancer

Merck KGaA, Darmstadt, Germany, And Pfizer Provide Update On Avelumab In Platinum-Resistant/Refractory Ovarian Cancer

DARMSTADT, Germany and NEW YORK, November 19, 2018 /PRNewswire/ -- Not intended for UK-based media     Merck KGaA, Darmstadt, Germany, and Pfizer Inc.

Carlos Ghosn, Apple, US-China Trade, Bitcoin and Pfizer - 5 Things You Must Know

Carlos Ghosn, Apple, US-China Trade, Bitcoin and Pfizer - 5 Things You Must Know

U.S. stocks futures indicated a firmer open Monday, even as reports suggest Renault CEO Carlos Ghosn faces arrest in Japan after Nissan said he had misused company funds and will be ousted as chairman; Apple is sliding again on fresh iPhone demand reports; U.S.-China trade tensions simmer; Bitcoin falls to a 13-month low and Pfizer plans 2019 durg price hikes.

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Jim Cramer says perception is determining how stocks trade right now -- and there's a lot of negativity.

Once Again It Is Breadth That Has My Eye

Breadth continues to outperform for now.

Pfizer Becomes #10 Most Shorted Dow Stock, Replacing Exxon Mobil

Pfizer Becomes #10 Most Shorted Dow Stock, Replacing Exxon Mobil

The most recent short interest data has been released for the 10/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.

New Clinical Oncology Collaboration Between Nektar And Pfizer To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, With Avelumab And Talazoparib Or Enzalutamide In Multiple Cancers

New Clinical Oncology Collaboration Between Nektar And Pfizer To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, With Avelumab And Talazoparib Or Enzalutamide In Multiple Cancers

SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc.

What Is the Dow Jones Industrial Average?

What Is the Dow Jones Industrial Average?

The Dow Jones Industrial Average is a price-weighted average of 30 large American publicly traded companies on the stock market.

I Can't Believe I Missed on Altria Stock

I Can't Believe I Missed on Altria Stock

Altria had been one of my staples in the past.

4 Scenarios That Will Impact the Market: Market Recon

4 Scenarios That Will Impact the Market: Market Recon

And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.

U.S. FDA Approves LORBRENA® (lorlatinib) For Previously-Treated ALK-Positive Metastatic NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) For Previously-Treated ALK-Positive Metastatic NSCLC

Pfizer Inc. (NYSE:PFE) today announced that the U.

Apple, Microsoft and Some Two-Dozen Other Stocks to Own in November

Apple, Microsoft and Some Two-Dozen Other Stocks to Own in November

Stephen 'Sarge' Guilfoyle gives you a rundown of what's in his portfolio as the new month gets rolling.

TheStreet Quant Rating: A (Buy)